Machine learning predicts conventional imaging metastasis-free survival (MFS) for oligometastatic castration-sensitive prostate cancer (omCSPC) using prostate-specific membrane antigen (PSMA) PET radiomics.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
PMID:

Abstract

PURPOSE: This study investigated imaging biomarkers derived from PSMA-PET acquired pre- and post-metastasis-directed therapy (MDT) to predict 2-year metastasis-free survival (MFS), which provides valuable early response assessment to improve patient outcomes.

Authors

  • Yufeng Cao
    Department of Radiation Oncology, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States of America.
  • Philip Sutera
    Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • William Silva Mendes
    Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Bardia Yousefi
    Department of Electrical and Computer Engineering, Laval University, Quebec City, QC G1V 0A6, Canada.
  • Tom Hrinivich
    Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Matthew Deek
    Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
  • Ryan Phillips
    Division of Pediatric Surgery, Children's Hospital Colorado, Aurora, CO, USA; Department of Surgery, University of Colorado School of Medicine, Aurora, CO, USA.
  • Danny Song
    Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Ana Kiess
    Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Ozan Cem Guler
    Baskent University Faculty of Medicine, Adana Dr Turgut Noyan Research and Treatment Center, Department of Radiation Oncology, Adana, Turkey.
  • Nese Torun
    Baskent University Faculty of Medicine, Adana Dr Turgut Noyan Research and Treatment Center, Department of Nuclear Medicine, Ankara, Turkey.
  • Mehmet Reyhan
    Baskent University Faculty of Medicine, Adana Dr Turgut Noyan Research and Treatment Center, Department of Nuclear Medicine, Ankara, Turkey.
  • Amit Sawant
    Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
  • Luigi Marchionni
    Weill Cornell Medicine, New York, NY, USA.
  • Nicole L Simone
    Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA, USA.
  • Phuoc Tran
    Faculty of Information Technology, Ton Duc Thang University, Ho Chi Minh City 700000, Vietnam.
  • Cem Onal
    Baskent University Faculty of Medicine, Adana Dr Turgut Noyan Research and Treatment Center, Department of Radiation Oncology, Adana, Turkey; Baskent University Faculty of Medicine, Department of Radiation Oncology, Ankara, Turkey. Electronic address: hcemonal@hotmail.com.
  • Lei Ren
    Department of Biomaterials, College of Materials, Xiamen University, Xiamen 361005, P.R. China.